Stavudine concentrations in women receiving postpartum antiretroviral treatment and their breastfeeding infants

Journal of Acquired Immune Deficiency Syndromes

Volumn 60, Issue 5, 2012, Pages 462-465

  Fogel, Jessica M ^a   Taha, Taha E ^b   Sun, Jin ^b   Hoover, Donald R ^c   Parsons, Teresa L ^a   Kumwenda, Johnstone J ^d   Mofenson, Lynne M ^e   Fowler, Mary Glenn ^a   Hendrix, Craig W ^e   Kumwenda, Newton I ^b   Eshleman, Susan H ^a   Mirochnick, Mark ^f  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d UNIVERSITY OF MALAWI   (Malawi)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

breast milk; HIV; mother to child transmission; stavudine concentrations

Indexed keywords

LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ARTICLE; BREAST FEEDING; BREAST MILK; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LIMIT OF QUANTITATION; MATERNAL PLASMA; MILK; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PUERPERIUM; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ANTI-HIV AGENTS; BREAST FEEDING; CHROMATOGRAPHY, LIQUID; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; MILK, HUMAN; POSTPARTUM PERIOD; STAVUDINE; TANDEM MASS SPECTROMETRY;

EID: 84864281569     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31825ddcfa     Document Type: Article

References (17)

1. Mirochnick M, Thomas T, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother. 2009;53: 1170-1176.
2. Schneider S, Peltier A, Gras A, et al. Efavirenz in human breast milk, mothers', and newborns' plasma. J Acquir Immune Defic Syndr. 2008;48: 450-454.
3. Shapiro RL, Holland DT, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis. 2005;192:720-727. (Pubitemid 41193069)
4. Weidle PJ, Zeh C, Martin A, et al. Nelfinavir and its active metabolite, hydroxy-t-butylamidenelfinavir (M8), are transferred in small quantities to breast milk and do not reach biologically significant concentrations in breast-feeding infants whose mothers are taking nelfinavir. Antimicrob Agents Chemother. 2011;55:5168-5171.
5. Fogel J, Li Q, Taha TE, et al. Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants. Clin Infect Dis. 2011;52:1069-1076.
6. Zeh C, Weidle PJ, Nafisa L, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med. 2011;8:e1000430.
7. Lidstrom J, Guay LA, Musoke P, et al. Multi-class drug resistance arises frequently in HIV-infected breastfeeding infants whose mothers initiate highly active antiretroviral therapy (HAART) post-partumAbstract T-124. Presented at: 17th Conference on Retroviruses and Opportunistic Infections; February 16-19, 2010; San Francisco, CA.
8. Colebunders R, Hodossy B, Burger D, et al. The effect of highly active antiretroviral treatment on viral load and antiretroviral drug levels in breast milk. AIDS. 2005;19:1912-1915. (Pubitemid 41546612)
9. World Health Organization (WHO). Antiretroviral therapy for HIV infection in adults and adolescents. 2010. Available at: http://whqlibdoc.who. int/publications/2010/9789241599764-eng.pdf. Accessed March 12, 2012.
10. Ministry of Health M. Clinical management of HIV in children and adults. 2011. Available at: http://www.who.int/hiv/pub/guidelines/malawi-art.pdf. Accessed March 12, 2012.
11. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk hiv-1 transmission. N Engl J Med. 2008;359:119-129. (Pubitemid 351962035)
12. Taha TE, Kumwenda J, Cole SR, et al. Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy. J Infect Dis. 2009;200: 1490-1497.
13. Kaul S, Kline MW, Church JA, et al. Determination of dosing guidelines for stavudine (2',3'-didehydro-3'-deoxythymidine) in children with human immunodeficiency virus infection. Antimicrob Agents Chemother. 2001;45:758-763. (Pubitemid 32182021)
14. Riddler SA, Anderson RE, Mellors JW. Antiretroviral activity of stavudine (2',3'-didehydro-3'-deoxythymidine, D4T). Antiviral Res. 1995;27: 189-203.
15. Wade NA, Unadkat JD, Huang S, et al. Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332. J Infect Dis. 2004;190: 2167-2174. (Pubitemid 39636365)
16. Liotta G, Pirillo M, Andreotti M, et al. Drug concentrations in breastfeeding infants of women receiving ARV for the prevention of postnatal transmission in Malawi. Presented at: 18th Conference on Retroviruses and Opportunistic Infections; February 27-March 2, 2011; Boston, MA.
17. Rezk NL, White N, Bridges AS, et al. Studies on antiretroviral drug concentrations in breast milk: validation of a liquid chromatography-tandem mass spectrometric method for the determination of 7 anti-human immunodeficiency virus medications. Ther Drug Monit. 2008;30:611-619.